Drug chirality and its clinical significance

Drugs

Volumn 52, Issue SUPPL. 5, 1996, Pages 1-12

  Hutt, A J ^a   Tan, S C ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ATRACURIUM; CIMETIDINE; DEXFENFLURAMINE; DEXTROPROPOXYPHENE; DISOPYRAMIDE; ENOXACIN; HEXOBARBITAL; IBUPROFEN; INDACRINONE; KETAMINE; KETOPROFEN; LEVOFLOXACIN; LEVOPROPOXYPHENE NAPSILATE; METHYLPHENOBARBITAL; PENICILLAMINE; PHENYLBUTAZONE; PROPRANOLOL; SOTALOL; SULFINPYRAZONE; THALIDOMIDE; TIMOLOL; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

AGING; CHIRALITY; CONFERENCE PAPER; DRUG CLEARANCE; DRUG METABOLISM; DRUG POTENCY; ENANTIOMER; GENDER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER CIRRHOSIS; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PHARMACOGENETICS; RACEMIC MIXTURE; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION;

EID: 0029999950     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600525-00003     Document Type: Conference Paper

References (78)

1. Ariens EJ, Wuis EW, Veringa EJ. Stereoselectivity of bioactive xenobiotics. A pre-Pasteur attitude in medicinal chemistry, pharmacokinetics and clinical pharmacology. Biochem Pharmacol 1988; 37: 9-18
2. Cushny AR. Biological relations of optically isomeric substances. London: Bailliere, Tindall and Cox, 1926
3. Mason S. The left hand of nature. New Scientist 1984; 101: 10-4
4. Matteson D. Through the chemical looking glass. New Scientist 1991; 132: 35-9
5. Hawkes N. Lateral thinking. Times Magazine: 5 Jun 1993: 30-1
6. Moran N. Drug firms sort their lefts from their rights. Independent on Sunday: 7 Nov 1993
7. Controulis J, Rebstock MC, Crooks HM. Chloramphenicol (chloromycetin) V. Synthesis. J Am Chem Soc 1949; 71: 2463-8
8. Rebstock MC, Crooks HM, Controulis J, et al. Chloramphenicol (chloromycetin) IV. Chemical studies. J Am Chem Soc 1949; 71: 2458-62
9. Ceccarini G, Maione AM. Variations of optical rotation of naproxen: polarimetric determination in the presence of non-chiral basic compounds. J Pharm Sci 1989; 78: 1053-4
10. Williams K, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333-54
11. Cahn RS, Ingold CK, Prelog V. The specification of asymmetric configuration in organic chemistry. Experientia 1956; 12: 81-94
12. Easson LH, Stedman E. Studies on the relationship between chemical constitution and physiological action. V. Molecular dissymmetry and physiological activity. Biochem J 1933; 27: 1257-66
13. Lehmann PAF, DeMiranda JFR, Ariens EJ. Stereoselectivity and affinity in molecular pharmacology. In: Jucker E, editor. Progress in drug research. Vol. 20. Basel: Birkhauser Verlag, 1976: 101-42
14. Lehmann PAF. Quantifying stereoselectivity or how to choose a pair of shoes when you have two left feet. Trend Pharmacol Sci 1982; 3: 103-6
15. Powell JR, Ambre JJ, Ruo TI. The efficacy and toxicity of drug stereoisomers. In: Wainer IW, Drayer DE, editors. Drug stereochemistry. Analytical methods and pharmacology. New York, Marcel Dekker, 1988: 245-70
16. Triggle DJ. On the other hand: the stereoselectivity of drug action at ion channels. Chirality 1994; 6: 58-62
17. Caldwell J, Winter SM. Hutt AJ. The pharmacological and toxicological significance of the stereochemistry of drug disposition. Xenobiotica 1988; 18 Suppl. 1: 59-70
18. Tucker GT, Lennard MS. Enantiomer specific pharmacokinetics. Pharmacol Ther 1990; 45: 309-29
19. Levy RH, Boddy AV. Stereoselectivity in pharmacokinetics: a general theory. Pharm Res 1991; 8: 551-6
20. Ariens EJ. Stereochemistry, a basis for sophisticated nonsense in pharmacokinetics and clinical pharmacology. Eur J Clin Pharmacol 1984; 26: 663-8
21. Eichelbaum M. Pharmacokinetic and pharmacodynamic consequences of stereoselective drug metabolism in man. Biochem Pharmacol 1988; 37: 93-6
22. Longstreth JA, Verapamil. A chiral challenge to the pharmacokinetic and pharmacodynamic assessment of bioavailability and bioequivalence. In: Wainer IW, editor. Drug stereochemistry. Analytical methods and pharmacology. 2nd ed. New York, Marcel Dekker, 1993: 315-36
23. Vogelgesang B, Echizen H, Schmidt E, et al. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol 1984; 18: 733-40
24. Echizen H, Vogelgesang B, Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther 1985; 38: 71-6
25. Coltart DJ, Shand DG. Plasma propranolol levels in the quantitative measurement of β-adrenergic blockade in man. BMJ 1970; 3: 731-4
26. Walle T, Webb JG, Bagwell EE, et al. Stereoselective delivery and actions of beta receptor antagonists. Biochem Pharmacol 1988; 37: 115-24
27. Walle T, Conradi EC, Walle UK, et al. 4-Hydroxypropranolol and its glucuronide after single and long-term doses of propranolol. Clin Pharmacol Ther 1980; 27: 22-31
28. Li G, Treiber G, Maier K, et al. Disposition of ibuprofen in patients with liver cirrhosis. Stereochemical considerations. Clin Pharmacokinet 1993; 25: 154-63
29. Avgerinos A, Hutt AJ. Interindividual variability in the enantiomeric disposition of ibuprofen following the oral administration of the racemic drug to healthy volunteers. Chirality 1990; 2: 249-56
30. Hutt AJ, Caldwell J. The metabolic chiral inversion of 2-arylpropionic acids - a novel route with pharmacological consequences. J Pharm Pharmacol 1983; 35: 693-704
31. Caldwell J, Hutt AJ. Fournel-Gigleux S. The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences. Biochem Pharmacol 1988; 37: 105-14
32. Williams KM. Enantiomers in arthritic disorders. Pharmacol Ther 1990; 46: 273-95
33. Evans AM. Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal antiinflamrnatory drugs. Eur J Clin Pharmacol 1992; 42: 237-56
34. Chen C-Y, Chen C-S. Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Br J Clin Pharmacol 1995; 40: 67-72
35. Chandler MHH, Scott SR, Blouin RA. Age associated stereoselective alterations in hexobarbital metabolism. Clin Pharmacol Ther 1988; 43: 436-41
36. Zhou H-H, Whelan E, Wood AJJ. Lack of effect of ageing on the stereochemical disposition of propranolol. Br J Clin Pharmacol 1992; 33: 121-3
37. Hooper WD, Qing MS. The influence of age and gender on the stereoselective metabolism and pharmacokinetics of mephobarbital in humans. Clin Pharmacol Ther 1990; 48: 633-40
38. Lennard MS, Tucker GT, Woods HF. Stereoselectivity in pharmacokinetics and drug metabolism. In: Taylor JB, editor. Comprehensive medicinal chemistry. Vol. 5. Biopharmaceutics. Oxford, Pergamon Press, 1990: 187-204
39. Lennard MS, Tucker GT, Silas JH, et al. Differential stereoselective metabolism of metoprolol in extensive and poor debrisoquin metabolisers. Clin Pharmacol Ther 1983; 34: 732-7
40. Walshe JM. Penicillamine, a new oral therapy for Wilson's Disease. Am J Med 1956; 21: 487-95
41. Glatt H, Oesch F. Mutagenicity of cysteine and penicillamine and its enantiomeric selectivity. Biochem Pharmacol 1985; 34: 3725-8
42. Tu J-B, Blackwell RQ, Lee PF. D,L-Penicillamine as a cause of optic axial neuritis. J Am Med Ass 1963; 185: 83-6
43. Walshe JM. Chirality of penicillamine [letter]. Lancet 1992; 339: 254
44. Lee A, Lawton NF. Penicillamine treatment of Wilson's disease and optic neuropathy. J Neurol Neurosurg Psych 1991; 58: 746
45. Blaschke G, Kraft HP, Fickentscher K et al. Chromatographische racemattrennung von thalidomid und teratogene wirkung der enantiomere. Arzneimittelforschung 1979; 29: 1640-2
46. Scott WJ, Fradkin R, Wilson JG. Non-confirmation of thalidomide-induced teratogenesis in rats and mice. Teratology 1977; 16: 333-6
47. Fabro S, Smith RL, Williams RT. Toxicity and teratogenicity of optical isomers of thalidomide. Nature 1967; 215: 269
48. Eriksson T, Bjorkman S, Roth B, et al. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide. Chirality 1995; 7: 44-52
49. Testa B, Carrupt P-A, Gal J. The so-called 'interconversion' of stereoisomeric drugs: an attempt at clarification. Chirality 1993; 5: 105-11
50. Banitt EH, Schmid JR, Newmark RA. Resolution of flecainide acetate, N-(2-piperidylmethyl)-2,5-bis (2,2,2-trifluoroethoxy) benzamide acetate and antiarrhythmic properties of the enantiomers. J Med Chem 1986; 29: 299-302
51. Hill RJ, Duff HJ, Sheldon RS. Determinants of stereospecific binding of type I antiarrhythmic drugs to cardiac sodium channels. Mol Pharmacol 1988; 34: 659-63
52. Gross AS, Mikus G, Fischer C, et al. Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol 1989; 28: 555-6
53. Richards R, Tattersfield AE. Bronchial β-adrenoceptor blockade following eyedrops of timolol and its isomer L-714, 465 in normal subjects. Br J Clin Pharmacol 1985; 20: 459-62
54. Fraunfelder FT, Barker AF. Respiratory effects of timolol. N Engl J Med 1985; 311: 1441
55. Baldwin JJ, Abrams WB. Stereochemically pure drugs, an industrial perspective. In: Wainer IW, Drayer DE, editors. Drug stereochemistry. Analytical methods and pharmacology. New York: Marcel Dekker, 1988: 311-56
56. Chiou GCW, Zhao F, Shen Z-H et al. Effects of D-timolol and L-timolol on ocular blood flow and ocular blood pressure. J Ocular Pharmacol 1990; 6: 23-9
57. Lanning CF, Harmel MH. Ketamine anesthesia. Ann Rev Med 1975; 26: 137-41
58. Eastman D, Hickey M, Hickey F. Ketamine misuse identified. Pharm J 1992; 248: 444
59. White PF, Schutter J, Shafer A, et al. Comparative pharmacology of the ketamine isomers. Br J Anaesth 1985; 57: 197-203
60. White PF, Ham J, Way WL, et al. Pharmacology of ketamine isomers in surgical patients. Anaesthesiology 1980; 52: 231-9
61. Vlasses PH, Irvin JD, Huber PB, et al. Pharmacology of the enantiomers and (-)-p-OH metabolite of indacrinone. Clin Pharmacol Ther 1981; 29: 798-807
62. Tobert JA, Cirillo VJ, Hitzenberger G, et al. Enhancement of uricosuric properties of indacrinone by manipulation of the enantiomer ratio. Clin Pharmacol Ther 1981; 29: 344-50
63. Gottesman MM, Paston I. Resistance to multiple chemotherapeutic agents in human cancer cells. Trend Pharmacol Sci 1988; 9: 54-8
64. Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 1990; 39: 787-92
65. Advani SV, Singh BN. Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol. Drugs 1995; 49: 664-79
66. Colatsky TJ. Antiarrhythmic drugs: where are we going? Pharmaceutical News 1995; 2: 17-23
67. De Camp WH. The FDA perspective on the development of stereoisomers. Chirality 1989; 1: 2-6
68. Cayen MN. Racemic mixtures and single stereoisomers: industrial concerns and issues in drug development. Chirality 1991; 3: 94-8
69. Rauws AG, Groen K. Current regulatory (draft) guidance on chiral medicinal products: Canada, EEC, Japan, United States. Chirality 1994; 6: 72-5
70. Brown JR. Stereochemical principles. Drug Info J 1990; 24: 117-20
71. Ariens EJ. Stereochemistry: a source of problems in medicinal chemistry. Med Res Rev 1986; 6: 451-66
72. Millership JS, Fitzpatrick A. Commonly used chiral drugs: a survey. Chirality 1993; 5: 573-6
73. Shindo H, Caldwell J. Development of chiral drugs in Japan: an update on regulatory and industrial opinion. Chirality 1995; 7: 349-52
74. Shindo H, Caldwell J. Regulatory aspects of the development of chiral drugs in Japan: a status report. Chirality 1991; 3: 91-3
75. Baba T, Murabayashi S, Aoyagi K, et al. Effects of dilevalol, an R, R-isomer of labetalol, on blood pressure and renal function in patients with mild-to-moderate essential hypertension. Eur J Clin Pharmacol 1988; 35: 9-15
76. Brittain RT, Drew GM, Levy GP. The α- and β-adrenoceptor blocking potencies of labetalol and its individual stereoisomers in anaesthetized dogs and in isolated tissues. Br J Pharmacol 1982; 77: 105-14
77. Anon. Neuromuscular blocking agent from Glaxo. Pharm J 1996; 256: 152
78. Sun Wai WYS, Flynn PJ. 51W89, the IR cis I'R cis isomer of atracurium. Anaesth Pharmacol Rev 1995; 3: 218-21